Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
37.36
-2.36 (-5.94%)
At close: Mar 31, 2025, 4:00 PM
36.00
-1.36 (-3.64%)
After-hours: Mar 31, 2025, 6:40 PM EDT
Apogee Therapeutics Employees
Apogee Therapeutics had 196 employees as of December 31, 2024. The number of employees increased by 105 or 115.38% compared to the previous year.
Employees
196
Change (1Y)
105
Growth (1Y)
115.38%
Revenue / Employee
n/a
Profits / Employee
-$929,316
Market Cap
2.17B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APGE News
- 4 weeks ago - Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - Benzinga
- 4 weeks ago - Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) - GlobeNewsWire
- 4 weeks ago - Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 - GlobeNewsWire
- 4 weeks ago - Apogee Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 4 months ago - Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - GlobeNewsWire